Table 2.
Cancer Cell | Dose/Duration | Findings | Mechanism | Reference |
---|---|---|---|---|
RINm5F (Insulinoma) | 12–100 µg/mL (24–48 h) | ↓ cell proliferation ↓ cell viability ↑ apoptosis |
↑ nitrate accumulation. ↑ TNFα production. |
[27] |
MIA-PaCa-2 (Pancreatic carcinoma), PANC-1 (Pancreatic carcinoma) | 20–120 µg/mL (48 h) | ↓ cell viability | ↑ PARP-cleavage | [21] |
MCF-7 (ER+) (Breast adenocarcinoma) | 40 mg RE powder filter (inserted into cigarette) (2 h) | ↓ BP levels and associated DNA adduct formation. | [28] | |
MCF-7 (ER+) (Breast adenocarcinoma), MDA-MB-468 (Breast adenocarcinoma) | 0.1%–20% (5–120 h) | IC50 ~90 µg/mL and 26.8 µg/mL | [29] | |
MCF-7 (ER+) (Breast adenocarcinoma), MDA-MB-231 (Breast adenocarcinoma) | 6.25–50 µg/mL (48 h) | ↓ cell viability IC50 ~20.42 µg/mL | [30] | |
MCF-7 (Breast adenocarcinoma) | 1–250 µg/mL (48 h) | ↓ cell proliferation IC50 187 µg/mL | [31] | |
MCF-7 (Breast adenocarcinoma) | 1.95–62.5 µg/mL (48 h) 3 REs standardized to 25.9%, 36.2%, 42.4% CA | ↓ cell proliferation IC50 9.95–13.89 µg/mL | [18] | |
SK-BR-3 (HER2+) (Breast adenocarcinoma), UACC-812 (HER2+) (Breast ductal carcinoma), T-47D (ER+) (Breast ductal carcinoma), MCF-7 (ER+) (Breast adenocarcinoma), MDA-MB-231 (Breast adenocarcinoma) | 10–120 µg/mL (48 h) | ↓ cell viability Enhanced effect of chemotherapeutics ↑ apoptosis ↓ cell transformation |
↑ FOS levels ↑ PARP cleavage ↓ HER2 ↓ ERBB2 ↓ ERα receptor. |
[32] |
TNFα (tumor necrosis factor), PARP (poly ADP ribose polymerase), BP (benzopyrene), Fos (FBJ murine osteogenic sarcoma virus), HER2 (human epidermal growth factor receptor 2), ERBB2 (HER2/neu gene), ERα (estrogen receptor α).